Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

BACKGROUND: Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Stephen R, Narendrula, Rashmi, Guo, Baoqing, Parissenti, Amadeo M, McCallum, Katherine L, Cull, Stephanie, Lannér, Carita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541348/
https://www.ncbi.nlm.nih.gov/pubmed/23194409
http://dx.doi.org/10.1186/1757-2215-5-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541348/
https://www.ncbi.nlm.nih.gov/pubmed/23194409
http://dx.doi.org/10.1186/1757-2215-5-40

Ejemplares similares